Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of rheumatoid arthritis~* Meets Class I, II or III of the ACR 1991 Revised Criteria~* RA seropositivity~* Stable dose of methotrexate~* Inadequate response to TNF inhibitors~Exclusion Criteria:~* Any prior treatment with lymphocyte depleting therapies~* History of active TB infection~* Known or screen test positive for specific viruses or indicators of viral infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A - PF-05280586 (Type: EXPERIMENTAL): None
- B - Rituximab EU (Type: ACTIVE_COMPARATOR): None
- C- Rituximab-US (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).